Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4769300 | 0.92 | MAPK14 (0.89) | MAPK14 | |
| Toluene SCHEMBL6225546 | 0.91 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL4765131 | 0.91 | MAPK14 (0.87) | MAPK14 | |
| SCHEMBL4762527 | 0.88 | MAPK14 (1.00) | MAPK14 | |
| Hydrochloric Acid SCHEMBL4762463 | 0.87 | MAPK14 (0.98) | MAPK14 | |
| Hydrochloric Acid SCHEMBL4763512 | 0.86 | MAPK14 (0.96) | MAPK14 | |
| SCHEMBL6780151 | 0.85 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4764009 | 0.80 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4762394 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4762364 | 0.78 | MAPK14 (1.00) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051974-A2 | NOVEL MOLECULES FOR REGULATING CELL DEATH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-09 | — | — | WO | claimed |
| EP-1537108-B1 | DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7259171-B2 | Di and trifluoro-triazolo-pyridines anti-inflammatory compounds | PFIZER INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-6949652-B2 | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1537108-A1 | DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040143119-A1 | Novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| US-20040092547-A1 | Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| US-20040053959-A1 | Novel processes and intermediates for preparing triazolo-pyridines | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040053958-A1 | Di and trifluoro-triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004020440-A1 | DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053958-A1 | Di and trifluoro-triazolo-pyridines anti-inflammatory compounds | MAPK1, CNKSR1, CCR2 | MAPK14 128/4885 |
| US-20040143119-A1 | Novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine | MAPK14, MAPKAPK2, MAPK15 | MAPK14 1/4885 |
| US-20040092547-A1 | Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines | MAPK1, MAP4K2, MAPK4 | MAPK14 44/4885 |
| US-20040053959-A1 | Novel processes and intermediates for preparing triazolo-pyridines | MAPK1, CNKSR1, MAPK3 | MAPK14 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.